AIML subsidiary NeuralCloud Solutions Signs Commercial Term Sheet with Culminate H Labs to Deploy MaxYield(TM) and Insight360(TM) into INTRINSICA's DNA-Guided Biofeedback Wellness Ecosystem

Executive Summary

• NeuralCloud Solutions Inc., a subsidiary of AI/ML Innovations Inc., entered into a non‑binding commercial term sheet with Culminate H Labs (CH Labs) to integrate its MaxYield™ ECG signal‑processing engine and Insight360™ analytics platform into CH Labs’ INTRINSICA digital health application.
• The collaboration aims to enhance real‑time cardiovascular biofeedback, correlate genetic markers with cardiac phenotypes, and expand AI‑driven cardiac intelligence across B2B health practitioner and consumer wearable markets.
• A pilot integration will begin with smart‑ring devices, followed by a staged rollout toward full commercial deployment and scalable per‑device economics.

Key Details

• Parties: NeuralCloud Solutions Inc. (wholly‑owned subsidiary of AI/ML Innovations Inc.) and Culminate H Labs, LLC (“CH Labs”).
• Agreement Type: Non‑binding commercial term sheet outlining future integration and commercialization of NeuralCloud’s MaxYield™ and Insight360™ technologies within CH Labs’ INTRINSICA platform.
• Technology Integration:
• MaxYield™ – AI‑based ECG denoising, beat‑level labeling, and waveform component extraction (P, QRS, T).
• Insight360™ – No‑code visualization/reporting dashboard for metrics such as HR, HRV, QT/QTc, ST segments, PR intervals, and trend‑based recovery markers.
• Strategic Benefits:
• Real‑time high‑fidelity ECG processing feeds directly into INTRINSICA’s genomic and metabolic models for continuous cardiovascular analysis.
• Enables correlation of DNA‑guided nutritional/epigenetic interventions with cardiac phenotypes.
• Strengthens the digital health twin architecture using PIRTM (Prime‑Indexed Recursive Tensor Mathematics) for auditable, ethically aligned recommendations.
• Rollout Plan:
• Initial pilot integration to validate ECG processing performance on smart‑ring devices.
• Upon successful validation, transition to structured commercialization with scalable per‑device economics aligned to CH Labs’ national and global distribution strategy.
• Executive Comments:
• Esmat Naikyar (President, NeuralCloud & CPO, AI/ML Innovations) highlighted the partnership as validation of embedding cardiac intelligence across precision medicine and genomic wellness.
• Juan Carlos Rodriguez (CEO, CH Labs) emphasized transforming wearable data into genomically‑informed clinical intelligence.
• Paul Duffy (Executive Chairman & CEO, AI/ML Innovations) noted the deal positions NeuralCloud at the core of biometric intelligence delivery for consumer health.

Notable Quotes

• “This partnership validates our strategy to embed cardiac intelligence across precision medicine and genomic wellness.” – Esmat Naikyar, President, NeuralCloud
• “Smart wearables and continuous health monitoring have democratized access to physiological data… integrating NeuralCloud's cardiac analytics allows us to deliver higher‑grade ECG processing combined with DNA‑guided precision nutritional intervention.” – Juan Carlos Rodriguez, CEO, CH Labs
• “This Term Sheet is an important validation of NeuralCloud's relevance to the fast‑moving consumer health and wearable innovation space.” – Paul Duffy, Executive Chairman & CEO, AI/ML Innovations